Show Notes
ARA-290, also called cibinetide, is an investigational 11-amino-acid peptide designed from erythropoietin biology to activate tissue-protective signaling without stimulating red-blood-cell production. In this episode, John Garrett, RN, breaks down the innate repair receptor, why ARA-290 has been studied in small-fiber neuropathy, what randomized human trials in sarcoidosis and type 2 diabetes actually found, and why objective nerve-fiber signals are interesting—but not the same thing as an approved therapy. You'll learn: • What ARA-290/cibinetide is • How it differs from full-length erythropoietin • What the innate repair receptor is • Why researchers studied corneal nerve fibers • What the 22-patient pilot trial showed • What the 64-patient phase 2b trial showed • Why pain and nerve-fiber endpoints did not tell exactly the same story • What is known—and not known—about safety • Why online ARA-290 products should not be assumed equivalent to trial material Explore the Peptides Explained app: app.peptidesexplained.info Learn more through Peptide Solutions: peptide-solutions.info Educational content only. ARA-290 is investigational and is not an FDA-approved treatment for neuropathy or any other clinical indication.
More from Peptides Explained
Seed oils may be hiding in more of your everyday foods than you realize. In this episode of Peptides Explained, host John talks with Cherie Calbom, MS—known as the Juice Lady—about seed oils, cooking fats, inflammation, and how to make more informed choices at the grocery store and when dining out.Cherie discusses how common seed oils are processed, why she recommends checking ingredient labels, and which alternatives she uses, including olive oil, avocado oil, coconut oil, ghee, and beef tallow. They also talk about omega-6 and omega-3 balance, cooking with different fats, and practical ways to make food swaps without giving up flavor.The conversation explores the history of seed oils and changing ideas about dietary fat and cholesterol. Cherie shares tips for spotting oils in packaged foods and describes resources for people who want to learn more, including her book The Truth About Seed Oils. Topics include: seed oils, cooking fats, inflammation, omega-6 and omega-3, food labels, nutrition, and healthy cooking.
Eli Lilly is taking legal action against businesses selling products labeled retatrutide. What do the lawsuits actually establish—and what don't they? John Garrett separates pending legal allegations from court findings, reviews the human trial evidence for the investigational triple agonist, and explains why molecular identity, purity, and pharmaceutical equivalence are not interchangeable. We also examine FDA restrictions, consumer safety, and the implications for clinics, vendors, and independent educators. Educational only; not medical or legal advice. Retatrutide is not FDA-approved. Sources: NEJM DOI 10.1056/NEJMoa2301972; FDA unapproved GLP-1 drug concerns; ClinicalTrials.gov NCT05929066 and NCT05882045.
Can peptide biology protect the brain from vascular damage? John follows a question that started with Vesugen into the biology of vascular cognitive impairment—endothelial dysfunction, hypoperfusion, blood-brain-barrier injury, mitochondrial stress, inflammation and neuronal damage. The episode maps Cerebrolysin, SS-31/elamipretide, ARA-290/cibinetide, Semax, Vesugen and GLP-1 receptor agonists onto different points in that cascade, then asks the question that matters: what does the human evidence actually support? Cerebrolysin provides the biggest surprise, with randomized vascular-dementia trials—but still low-certainty evidence. Educational only; not medical advice.
Everyone keeps calling belly fat "visceral fat." That is not how anatomy works. In this crossover episode, John breaks down the difference between visceral and subcutaneous fat, why visceral adipose tissue matters metabolically, how it is actually measured, what waist circumference can and cannot tell you, and what the evidence says about GLP-1 therapies and tesamorelin.
Vesugen is only three amino acids long: lysine, glutamate, and aspartate — KED. Yet it is promoted as a vascular bioregulator that may support endothelial health and even "rejuvenate" aging blood vessels. In this episode, John Garrett looks at what the endothelial research actually measured, the proposed gene-regulation mechanism, a small human blood-flow report, and the large gap between an interesting cell signal and a proven cardiovascular therapy. No hype. No dismissal. Just the biology, the evidence, and what remains unknown. INSTAGRAM CAPTION Three amino acids. K. E. D. And somehow that became a claim about "rejuvenating" aging blood vessels. Vesugen is one of the more interesting Khavinson bioregulator peptides because there is actual published endothelial-cell research behind the concept. But there is a big difference between: changing a cell marker improving endothelial function and preventing cardiovascular disease. In the new episode of Peptides Explained, I break down the mechanism, the human signal, the evidence gaps, and the question that matters most: Can Vesugen actually make aging blood vessels younger — or is the marketing way ahead of the science? Educational only. Not medical advice. #PeptidesExplained #Vesugen #KEDPeptide #Peptides #Longevity #VascularHealth #EndothelialHealth #CardiovascularHealth #HealthyAging #Biohacking #PeptideScience #MedicalScience